Polar Capital Holdings’s Enliven Therapeutics ELVN Stock Holding History

Polar Capital Holdings’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$199M	Buy	5,065,933 +1,552,253	+44%	+$43M	0.71%	39
2025 Q4	$54.1M	Buy	3,513,680 +418,673	+14%	+$8.34M	0.21%	93
2025 Q3	$63.4M	Buy	3,095,007 +44,713	+1%	+$901K	0.3%	83
2025 Q2	$61.2M	Buy	3,050,294 +685,000	+29%	+$13M	0.32%	78
2025 Q1	$46.5M	Sell	2,365,294 -24,374	-1%	-$525K	0.28%	99
2024 Q4	$53.8M	Buy	2,389,668 +1,739,668	+268%	+$45.1M	0.3%	88
2024 Q3	$16.6M	Hold	650,000	–	–	0.08%	160
2024 Q2	$15.2M	Buy	+650,000	New	+$13.7M	0.09%	159

Other funds holding ELVN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Polar Capital Holdings's ELVN Position: Q1 2026 in Review

Polar Capital Holdings increased its Enliven Therapeutics (ELVN) stake by 44% in Q1 2026, buying an estimated $43M and bringing the position to 5,065,933 shares worth $199M. The position accounts for 0.71% of the portfolio, ranked #39.

Polar Capital Holdings first reported a position in ELVN in Q2 2024 and has held it in 8 quarters since. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

Polar Capital Holdings held 5,065,933 shares of Enliven Therapeutics worth $199M as of Q1 2026.
Polar Capital Holdings bought 1,552,253 Enliven Therapeutics shares in Q1 2026, an estimated $43M.
Enliven Therapeutics made up 0.71% of Polar Capital Holdings's portfolio in Q1 2026, its #39 holding.
Polar Capital Holdings first reported a position in Enliven Therapeutics in Q2 2024 and has held it in 8 quarters since.
170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Polar Capital Holdings's 13F filing for Q1 2026, filed 15 May 2026.